BioTelemetry, Inc. (BEAT) EPS Estimated At $0.31

October 13, 2018 - By Peter Erickson

BioTelemetry, Inc. (NASDAQ:BEAT) LogoInvestors sentiment decreased to 1.04 in Q2 2018. Its down 0.34, from 1.38 in 2018Q1. It is negative, as 12 investors sold BioTelemetry, Inc. shares while 80 reduced holdings. 39 funds opened positions while 57 raised stakes. 29.62 million shares or 0.63% more from 29.44 million shares in 2018Q1 were reported.
Hanseatic Mngmt Incorporated stated it has 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Riverhead Capital Mgmt reported 3,637 shares. 135,000 are held by Teton Advisors. Morgan Stanley has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Bank & Trust Of Montreal Can accumulated 1,445 shares or 0% of the stock. Pdt Prtnrs Limited Liability Co reported 0.21% stake. Rothschild Asset Mgmt Inc reported 0.02% in BioTelemetry, Inc. (NASDAQ:BEAT). Eam Llc invested in 0.72% or 102,013 shares. 10,738 were reported by Metropolitan Life Insur Ny. Castleark Mngmt Ltd Liability Corp holds 0.42% or 304,721 shares. Ubs Asset Mngmt Americas invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Walleye Trading Ltd Limited Liability Company stated it has 1,088 shares. Aperio Group Limited Company has invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). 1832 Asset Lp owns 800 shares. Mutual Of America Capital Mgmt Llc stated it has 114 shares.

Analysts expect BioTelemetry, Inc. (NASDAQ:BEAT) to report $0.31 EPS on November, 6.They anticipate $0.15 EPS change or 93.75 % from last quarter’s $0.16 EPS. BEAT’s profit would be $10.14M giving it 42.99 P/E if the $0.31 EPS is correct. After having $0.46 EPS previously, BioTelemetry, Inc.’s analysts see -32.61 % EPS growth. The stock increased 2.97% or $1.54 during the last trading session, reaching $53.31. About 446,567 shares traded or 1.40% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 55.22% since October 13, 2017 and is uptrending. It has outperformed by 39.60% the S&P500.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 2 analyst reports since June 20, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, September 14 by Raymond James.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.74 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.